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ABSTRACT   
Vasitis nodosa is a benign proliferation of vas deferens epithelium, thought to be a 
response to trauma or obstruction, usually vasectomy. Although histologic features mimic 
malignancy, diagnosis is usually straightforward due to the clinical context. We analyzed 
21 specimens with vasitis or epididymitis nodosa with antibodies to PAX8, CD10, p63, 
alpha-methyl-acyl-coA-racemase (AMACR), GATA3, prostein, NKX3.1, and prostate-
specific antigen (PSA). Two diagnostically problematic cases included 1) florid bladder 
muscle involvement after prostatectomy and 2) involvement of the ampulla and ejaculatory 
duct in a radical prostatectomy specimen. Vasitis nodosa was excluded in 3 additional 
histologic mimics (2 post-treatment prostate cancers and 1 bladder cancer). PAX8 yielded 
consistent positive (100%) nuclear staining in the proliferative glands of vasitis nodosa, 
often stronger and more uniform than native vas deferens. CD10 labeling was common but 
also labeled secretions and other structures. Labeling for p63 was often basally located in 
glands with a multilayered appearance, but often markedly attenuated or lacking in the 
proliferative glands compared to native epithelium. AMACR positivity was variable but 
often present (19/21). PSA, prostein, and NKX3.1 were consistently negative. Rare 
problematic cases of vasitis nodosa include "invasion" of the ejaculatory duct at the 
prostate and involvement of bladder muscle after prostatectomy. The proliferative vasitis 
nodosa glands often have a prostate cancer-like staining pattern with variable AMACR 
positivity and negative or patchy p63. However, reliable positivity for PAX8, patchy 
GATA3, and negative staining for PSA, NKX3.1, and prostein aid in distinguishing from 
prostate cancer and tubular variants of bladder cancer. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Kezlarian et al – Vasitis nodosa immunohistochemistry 
 3 
Key words: Vasitis nodosa, immunohistochemistry, prostate cancer, GATA3, PAX8, 
NKX3.1 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Kezlarian et al – Vasitis nodosa immunohistochemistry 
 4 
Introduction 
 
Vasitis nodosa is a benign proliferation of vas deferens epithelium, thought to occur 
as a response to mechanical obstruction or traumatic injury.  It is hypothesized that 
mechanical obstruction leads to increased intraluminal pressure and resulting spermatic 
fluid leakage. This extravasation of fluid is thought to result in subsequent inflammation 
and glandular proliferation.  Vasitis nodosa typically occurs in the setting of prior 
vasectomy, but has been reported in other clinical scenarios, such as trauma, primary 
infertility, cystitis, or surgery. Clinical findings can include palpable nodules, scrotal pain, 
or swelling [1-4].   
 
In the usual clinical context (characteristically post-vasectomy), vasitis nodosa is a 
relatively straightforward diagnosis, despite that it is known to have worrisome histologic 
characteristics, such as prominent nucleoli, pseudoinvasive growth pattern, and vascular 
and perineural invasion [5-8].  However, we have encountered rare clinical scenarios in 
which vasitis nodosa presented a diagnostic challenge, including occurrence at the ampulla 
of the vas deferens (the tortuous and dilated segment at the junction with the prostate and 
ejaculatory duct) in a prostate cancer specimen and in the wall of a cystectomy specimen 
after radical prostatectomy. Conversely, we have encountered occasional cancers that 
raised morphologic consideration of vasitis nodosa in these sites. Although a few 
immunohistochemical markers have been previously studied vasitis nodosa, we sought to 
characterize the immunohistochemical staining pattern of vasitis nodosa with a modern 
antibody panel to aid in such scenarios. 
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Materials and Methods  
After approval by the Institutional Review Board of the Henry Ford Health System, 
we queried the databases at two academic health systems (Indiana University Health and 
Henry Ford Health System) for cases of vasitis nodosa, epididymitis nodosa, and sperm 
granuloma, yielding 29 specimens.  These cases were reviewed, of which 21 from 18 
patients were ultimately confirmed to have vasitis or epididymitis nodosa and were 
included in the final cohort.   
The specimens were from primarily vasectomy, vasovasostomy, or excisional 
biopsy samples, whereas 2 of the problematic diagnoses were found in resection specimens 
(1 radical prostatectomy and 1 cystectomy). Three cancer specimens (2 prostate cancers 
and 1 bladder cancer) for which morphology raised consideration of vasitis nodosa were 
also studied. Each specimen was fixed in 10% formalin solution and embedded in paraffin 
wax.  Sections of 4-micron thickness were cut, stained with hematoxylin and eosin, and 
microscopically examined. 
Each specimen was scored for presence or absence pseudoinvasive growth pattern, 
perineural invasion, vascular invasion, and prominent nucleoli.  Clinical parameters, 
including age, reason for surgery, history of obstructive event, and history of previous 
chemotherapy or radiation were gathered.  Using 4 um thick tissue sections, 
immunohistochemistry was performed using DAKO Link Autostainer automated system 
(DAKO Corp).  Immunohistochemical stains were performed using anti-GATA3 
monoclonal mouse antibody (1:200; Biocare, Concord, CA), anti-PAX8 monoclonal 
mouse antibody (1:50; Biocare, Concord, CA), anti-CD10 monoclonal mouse antibody 
(1:75; DAKO, Carpinteria, CA), anti-prostein (p501s) monoclonal mouse antibody 
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(1:1000; DAKO, Carpinteria, CA), anti-prostate-specific antigen monoclonal rabbit 
antibody (1:6000; DAKO, Carpinteria, CA), anti-NKX3.1 polyclonal rabbit antibody 
(1:50, Biocare, Concord, CA); and a PIN cocktail consisting of anti-p63 and alpha-
methylacyl-CoA racemase (AMACR), monoclonal mouse antibodies (Biocare, Concord, 
CA). Hematoxylin was used as a counterstain. Strength and pattern of staining, in addition 
to percent of lesional tissue staining positive were recorded. 
 
Results  
Proliferative glands with prominent nucleoli were commonly present, in 19 of 21 
cases, with infrequent perineural localization (3/21 cases).  In the vasitis nodosa tissues 
(Figures 1-2), PAX8 yielded consistent positive (100%) nuclear staining in the lesional 
glands, often stronger and more uniform than native vas deferens, and GATA3 was often 
positive (10/18). CD10 staining, was consistently positive (21/21 cases), but in addition to 
the proliferative glands, this staining also labeled luminal and extra-cellular secretions, and 
the basement membranes and apical surfaces of native and proliferative glands.  Labeling 
for p63 was often basally located, resembling the basal cell pattern expected of prostate 
glandular tissue, but often markedly attenuated or lacking in the proliferative glands 
compared to the native epithelium. Labeling for GATA3 largely corresponded to the same 
areas as p63 positivity, preferentially glands with a more multilayered appearance. Overall, 
12/21 cases demonstrated p63 positive basally-located cells, although this was variable 
within a given specimen, ranging from 10-80% of glands positive (median 28%). 
Specimens without any p63-positive cells primarily corresponded to small foci of vasitis 
nodosa with only a few monolayered-appearing glands.  AMACR positivity was variable 
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but often present (18/21), ranging from weak to strong staining.  No example of vasitis 
nodosa included in this study was positive for PSA, prostein, or NKX3.1 (0/20). Two 
diagnostic challenging scenarios included: 1) a radical prostatectomy specimen from a 74-
year-old man, performed for Gleason 3+4=7 prostate cancer (Figure 3A-D), and 2) a 
cystectomy specimen from a 70-year-old man, performed for severe radiation cystitis after 
prostatectomy (Figure 3E-F). The cystectomy specimen demonstrated bladder muscle and 
florid soft tissue involvement by proliferative glands, mimicking recurrent prostate cancer 
invading the bladder wall.  The radical prostatectomy specimen showed involvement of the 
ampulla and ejaculatory duct, mimicking seminal vesicle invasion. 
 
Vasitis nodosa mimics 
 Three cancers for which vasitis nodosa was considered in the differential diagnosis 
were also studied, including 2 post-treatment prostate cancers (1 radiation and 1 androgen 
deprivation) and 1 post-neoadjuvant chemotherapy treated bladder cancer with a small 
amount of residual tumor showing gland-like tubular architecture. The possibility of vasitis 
nodosa was considered in both prostate cancer cases due to juxtaposition of tumor to the 
ejaculatory duct or seminal vesicle, 1 appearing discontinuous with the remainder of the 
tumor volume, likely representing treatment response of the intervening areas. These were 
positive for PSA (2/2), AMACR (2/2), and prostein (1/1), negative for PAX8 (0/2), p63, 
(0/2) and high molecular weight keratin (0/1). 
The bladder cancer contained very little residual tumor, which exclusively had a 
small tubular pattern (Figure 4). Interestingly, most of the tumor in the prior transurethral 
resection was usual urothelial carcinoma; however, this tubular morphology was focally 
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present pre-treatment. These tumor gland-like structures were negative for PAX8, PSA, 
and prostein, and positive for p63 and GATA3 in a patchy but substantially non-basal 
distribution. CD10 demonstrated patchy labeling but was negative in some of the most 
cytologically bland tubular areas, arguing against vasitis nodosa.  
 
Discussion 
Vasitis nodosa is a benign proliferation of the vas deferens epithelium, typically 
occurring post-vasectomy, or after other injury or transection. Histologic features are 
known to include prominent nucleoli, pseudoinvasive growth pattern, and perineural 
invasion, resembling prostate cancer. However, the clinical context is usually 
straightforward, since patients often have a known history of vasectomy and no known 
prostate cancer, and since specimens usually represent tissue quite a distance from the 
prostate.  Nevertheless, we have identified in this study 2 cases in which vasitis nodosa 
was found in a worrisome clinical scenario, mimicking malignancy, and 3 cases of prostate 
or bladder cancer raising morphologic consideration of vasitis nodosa, prompting us to 
establish an immunohistochemical profile of vasitis nodosa using a modern antibody panel.  
The main immunohistochemical marker in contemporary practice that has been 
previously studied in vasitis nodosa is CD10, which has been found to be consistently 
positive in native vas deferens [9] as well as vasitis nodosa [10]; however, this is probably 
of limited diagnostic utility, as it also labels basement membranes and apical surface of the 
native and proliferative epithelia and luminal and extra-cellular extravasated fluid as well. 
Interestingly, we found native vas deferens to demonstrate a distinct basal-like layer of p63 
positive cells, whereas the proliferative glands had variable positivity, including sometimes 
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a substantial number of small glands without p63-positive cells.  Even within the same 
surgical specimen, smaller glands with a monolayered appearance sometimes lacked p63-
staining cells, whereas larger glands with multilayered epithelium demonstrated p63 
staining like the native vas deferens.    
PAX8 is a member of the paired box family of genes, and it is involved in the 
development of tissues of the Wollfian (mesonephric) duct, kidney, Mullerian organs, and 
the thyroid [11]. As the vas deferens is a Wolffian structure [12], the positivity for PAX8 
confirmed by this study may be of value in distinguishing vasitis nodosa from other 
epithelial proliferations, such as prostate cancer or a bladder cancer variant.  PAX8 has 
been demonstrated to be consistently negative in adenocarcinoma of the prostate, and 
usually negative in urothelial carcinomas [13-15]. Other studies have noted PAX8 
positivity in the normal vas deferens [11, 12], and PAX2 labeling in related structures [16]. 
However, it is interesting that in the current study of vasitis nodosa, the staining 
characteristics of the proliferative vasitis nodosa glands differ somewhat from that of the 
normal vas deferens, particularly in that PAX8 labeling was sometimes stronger and more 
uniform and that GATA3 and p63 labeling can be decreased or absent. GATA3 is a 
transcription factor with critical roles in a variety of tissues [17], including development of 
Wolffian duct structures [18]. It has been recently found to be a helpful marker, although 
multispecific, for a variety of tumors, especially urothelial carcinoma and breast 
carcinoma, with consistent negative staining in prostate cancer [19-21].   
This study also reveals a previously undocumented potential diagnostic pitfall in 
this differential diagnosis.  The combination of AMACR positivity and absence of basal 
cells with p63 staining is frequently employed in the diagnosis of prostate cancer.  A 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Kezlarian et al – Vasitis nodosa immunohistochemistry 
 10 
subset of the benign glands of vasitis nodosa can demonstrate a prostate cancer-like 
staining pattern, with moderate to strong AMACR and lack of p63 positive cell layer.  
Indeed, 2 cases included in the studied occurred in scenarios where prostate cancer was a 
major consideration, 1 in a radical prostatectomy for cancer, in which the proliferation 
occurred ampulla of the vas deferens (the tortuous and dilated segment at the junction with 
the prostate and ejaculatory duct), mimicking seminal vesicle invasion (pT3b disease) and 
1 in a cystectomy specimen for radiation cystitis after prostatectomy, in which the 
proliferation mimicked recurrent cancer invading bladder wall. To our knowledge, these 
scenarios have not been previously reported, but they may represent uncommon contexts in 
which a proliferation of vas deferens occurs due to transection (in the case of prior 
prostatectomy) or obstruction (for unknown reasons in the radical prostatectomy case). 
Occurrence at the prostate is likely quite rare, as we identified only 1 case from hundreds 
of radical prostatectomy specimens evaluated in our institution annually, although it is also 
possible that subtle forms are underrecognized. 
Other considerations that may be entertained for vasitis nodosa involving the 
bladder wall include deceptive urothelial carcinoma variants [22, 23], such as urothelial 
carcinoma with small tubules [24, 25], or microcytic urothelial carcinoma [26, 27]. This 
difficulty could be further compounded by the fact that vasitis nodosa can be GATA3 and 
p63 positive, although as we have shown here, often in a patchy distribution. Awareness of 
these staining patterns and the consistent PAX8 positive, PSA, prostein, and NKX3.1-
negative phenotype of vasitis nodosa may aid the practicing pathologist in avoiding the 
potential pitfall of misdiagnosis of vasitis nodosa as malignancy. Conversely, we also 
report here 3 examples of malignancy that raised differential diagnostic consideration of 
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vasitis nodosa, all in the post-treatment setting, including 2 prostate cancers in the 
ejaculatory duct area and 1 bladder cancer with small tubular structures. For prostate 
cancer, the positivity for PSA, NKX3.1, or prostein, combined with negative PAX8 and 
lack of basal distribution of p63 positive cells may be helpful in such a context. Similarly, 
awareness of these staining patterns, may be helpful in arguing against consideration of 
vasitis nodosa in the context of a tubular variant of bladder cancer.  
 
Conclusions  
In addition to characterizing the immunohistochemical signature of vasitis nodosa, 
this study unearthed novel diagnostic pitfalls. Rare problematic lesions include "invasion" 
of the ejaculatory duct at the prostate and involvement of bladder muscle after 
prostatectomy. Proliferative vasitis nodosa glands often have a prostate cancer-like staining 
pattern with variable AMACR positivity and negative or patchy p63, in contrast to the 
native vas deferens.  GATA3 is also often positive, generally in a similar distribution to 
p63. Reliable positivity for PAX8 and negative staining for PSA, NKX3.1, and prostein aid 
in distinguishing vasitis nodosa from prostate cancer. 
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Figure legends: 
Figure 1: This case of vasitis nodosa (A, 200×, hematoxylin and eosin) demonstrates the 
native vas deferens lumen at right and proliferative glands at left. Higher magnification 
demonstrates variably monolayered to multilayered epithelium with clear to eosinophilic 
cytoplasm and prominent nucleoli (B, 400×, hematoxylin and eosin). Staining for PAX8 
(C, 200×, anti-PAX8 immunohistochemistry) labels the vasitis nodosa (left) and native 
lumen (right). Antibody to p63 (D, nuclear staining in dual antibody, single color cocktail, 
200×, anti-p63 and alpha-methylacyl-CoA racemase immunohistochemistry) reveals a 
p63-positive, basally-located cell layer in the native vas deferens (right) but not the vasitis 
nodosa (left). Staining for alpha-methyl-acyl-coA-racemase (cytoplasmic labeling) shows 
similar intensity in both areas. Staining for GATA3 (E, 200×, anti-GATA3 
immunohistochemistry) labels the native vas deferens lumen (right) but not the 
proliferative glands (left). CD10 (F, 200×, anti-CD10 immunohistochemistry) staining 
labels the apical cytoplasm and faintly the basal layer of the native vas deferens (right) but 
strongly labels all vasitis nodosa glands throughout the cells (left). 
 
Figure 2: Vasitis nodosa glands from a vasovasostomy (vasectomy reversal) (A, 200× 
magnification hematoxylin and eosin) demonstrate a pseudoinfiltrative growth pattern and 
cytologic atypia with prominent nucleoli; however, sperm are visible in lumina (B, 400× 
magnification hematoxylin and eosin). Dual antibody, single color antibody cocktail for 
p63 and alpha-methyl-acyl-coA-racemase (AMACR, C, 200×) reveals a basally-located, 
p63-positive cell layer in a few glands at left; however, the proliferative glands more 
distant from the native lumen have no such layer and exhibit strong labeling for AMACR, 
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mimicking prostatic adenocarcinoma (right). Staining for PAX8 labels the majority of 
vasitis nodosa glands consistently (D, 200×, anti-PAX8 immunohistochemistry). The same 
field with anti-GATA immunohistochemical staining (E, 200×) shows focal GATA3 
labeling at left, similar to p63, but absence at right. Staining for NKX3.1 (F, anti-NKX3.1 
immunohistochemistry, 200×) is entirely negative.  
 
Figure 3: In this example of vasitis nodosa mimicking seminal vesicle invasion (A, 100×, 
hematoxylin and eosin), the vasitis nodosa glands (left) are located near the ejaculatory 
duct (upper right). There is amyloid deposition around the ejaculatory duct epithelium but 
not the vasitis nodosa. At high magnification, the vasitis nodosa glands have prominent 
nucleoli (B, 400×, hematoxylin and eosin), mimicking prostate cancer. Vasitis nodosa 
glands demonstrate uniform nuclear staining for PAX8 (C, 400×, anti-PAX8 
immunohistochemistry) and a subset of glands have p63-positive cells (D, bottom, nuclear, 
400×, anti-p63 and alpha-methylacyl-CoA racemase single-color immunohistochemistry), 
with both p63-positive and negative glands showing substantial staining for alpha-methyl-
acyl-coA-racemase (D cytoplasmic). In another case of vasitis nodosa infiltrating the 
bladder wall after prostatectomy (E, 100×, hematoxylin and eosin), glands with prominent 
nucleoli are present between muscularis propria bundles (F, 400×, hematoxylin and eosin).  
 
Figure 4: In this case of urothelial carcinoma with small tubules, raising consideration of 
vasitis nodosa, small tubular structures infiltrate the muscularis propria (A, 200×, B, 400×, 
hematoxylin and eosin). In contrast to the vasitis nodosa cases, staining for p63 varies from 
patchy (C, 200×, anti-p63 immunohistochemistry) to diffuse (D, 200×, anti-p63 
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immunohistochemistry) in a non-basal distribution. There is diffuse, staining for GATA3, 
even in gland-like structures with a cuboidal, monolayered appearance (E, 200×, anti-
GATA3 immunohistochemistry). Staining for PAX8 (F, 400×, anti-PAX8 
immunohistochemistry) is entirely negative.   
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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  Vasitis nodosa 
Prostate cancer mimicking 
vasitis nodosa 
Urothelial carcinoma 
mimicking vasitis nodosa 
p63 12/21, often basally located 0/2 1/1, patchy 
AMACR 
18/21, variable, weak to 
strong 
2/2, strong ND 
GATA3 10/18, patchy or basal ND 1/1, patchy, nonbasal 
PAX8 
21/21, more uniform in 
vasitis nodosa than normal 
lumen 
0/2 0/1 
CD10 
21/21, diffuse in glands and 
secretions 
ND 
1/1, patchy but some 
cuboidal glands entirely 
negative 
PSA 0/20 2/2 0/1 
Prostein 0/20 1/1 0/1 
NKX3.1 0/20 ND ND 
 
Table 1: Summary of immunohistochemical markers in vasitis nodosa and mimics. 
Abbreviations: AMACR – alpha-methylacyl-CoA racemase; PSA – prostate-specific 
antigen; ND – not done  
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Highlights 
 Vasitis nodosa is a benign proliferation with worrisome histologic features 
 Immunohistochemical characteristics can mimic prostate cancer (AMACR+, p63-) 
 However, glands consistently label for PAX8 and not for prostate markers 
 Labeling for GATA3 and p63 is usually basal, but lacking in small glands 
